316 related articles for article (PubMed ID: 27155840)
1. Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells.
Alasmari A; Lin SC; Dibart S; Salih E
Clin Exp Metastasis; 2016 Aug; 33(6):563-88. PubMed ID: 27155840
[TBL] [Abstract][Full Text] [Related]
2. Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes in mice.
Tsuboi K; Hasegawa T; Yamamoto T; Sasaki M; Hongo H; de Freitas PH; Shimizu T; Takahata M; Oda K; Michigami T; Li M; Kitagawa Y; Amizuka N
Histochem Cell Biol; 2016 Sep; 146(3):337-50. PubMed ID: 27235014
[TBL] [Abstract][Full Text] [Related]
3. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional cancer-bone metastasis model using ex-vivo co-cultures of live calvarial bones and cancer cells.
Curtin P; Youm H; Salih E
Biomaterials; 2012 Feb; 33(4):1065-78. PubMed ID: 22071100
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
6. Alendronate promotes bone formation by inhibiting protein prenylation in osteoblasts in rat tooth replantation model.
Komatsu K; Shimada A; Shibata T; Wada S; Ideno H; Nakashima K; Amizuka N; Noda M; Nifuji A
J Endocrinol; 2013 Nov; 219(2):145-58. PubMed ID: 24096963
[TBL] [Abstract][Full Text] [Related]
7. Zoledronate promotes bone formation by blocking osteocyte-osteoblast communication during bone defect healing.
Cui P; Liu H; Sun J; Amizuka N; Sun Q; Li M
Histol Histopathol; 2018 Jan; 33(1):89-99. PubMed ID: 28345127
[TBL] [Abstract][Full Text] [Related]
8. Bone resorption and bone metastasis risk.
Mathis KM; Sturgeon KM; Winkels RM; Wiskemann J; De Souza MJ; Schmitz KH
Med Hypotheses; 2018 Sep; 118():36-41. PubMed ID: 30037612
[TBL] [Abstract][Full Text] [Related]
9. The effects of mechanically loaded osteocytes and inflammation on bone remodeling in a bisphosphonate-induced environment.
George EL; Truesdell SL; Magyar AL; Saunders MM
Bone; 2019 Oct; 127():460-473. PubMed ID: 31301402
[TBL] [Abstract][Full Text] [Related]
10. Alendronate-induced atypical bone fracture: evidence that the drug inhibits osteogenesis.
Patntirapong S; Singhatanadgit W; Arphavasin S
J Clin Pharm Ther; 2014 Aug; 39(4):349-53. PubMed ID: 24661151
[TBL] [Abstract][Full Text] [Related]
11. [Bone targeting agents: bisphosphonates].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of suppressing osteoclast formation versus function.
Teitelbaum SL
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii61-ii63. PubMed ID: 27856662
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis.
Holmberg AR; Lerner UH; Alayia AA; Al-Mohanna M; Adra C; Marquez M; Meurling L; Nilsson S
Int J Oncol; 2010 Sep; 37(3):563-7. PubMed ID: 20664925
[TBL] [Abstract][Full Text] [Related]
14. Osteocytes and Bone Metastasis.
Riquelme MA; Cardenas ER; Jiang JX
Front Endocrinol (Lausanne); 2020; 11():567844. PubMed ID: 33162934
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and clinical efficacy of bisphosphonates.
Berenson JR; Lipton A
Curr Opin Oncol; 1998 Nov; 10(6):566-71. PubMed ID: 9818237
[TBL] [Abstract][Full Text] [Related]
16. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.
Plotkin LI; Lezcano V; Thostenson J; Weinstein RS; Manolagas SC; Bellido T
J Bone Miner Res; 2008 Nov; 23(11):1712-21. PubMed ID: 18597631
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells.
Kucukzeybek Y; Gorumlu G; Cengiz E; Karabulut B; Sezgin C; Atmaca H; Sanli UA; Uzunoglu S; Uslu R
J Int Med Res; 2010; 38(5):1663-72. PubMed ID: 21309480
[TBL] [Abstract][Full Text] [Related]
18. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Boissier S; Magnetto S; Frappart L; Cuzin B; Ebetino FH; Delmas PD; Clezardin P
Cancer Res; 1997 Sep; 57(18):3890-4. PubMed ID: 9307266
[TBL] [Abstract][Full Text] [Related]
20. [Molecular basis of bone metastasis formation and its targeted therapy].
Tímár J
Magy Onkol; 2010 Mar; 54(1):59-64. PubMed ID: 20350869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
